Preventing relapse in high-risk T-cell leukemia after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial evaluates the effectiveness of combining demethylating agents, such as azacitidine or decitabine, with venetoclax to prevent relapse in high-risk T-cell lymphoblastic lymphoma/leukemia patients following allogeneic hematopoietic stem cell transplantation. The study compares outcomes of patients receiving this treatment to historical controls who did not receive prophylactic therapy. Key endpoints include relapse-free survival, overall survival, and the incidence of graft-versus-host disease. The goal is to establish a safer and more effective relapse prevention strategy for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1.14-55 years old, male,or female.
* 2.Patients with allo-HSCT due to T-LBL/ALL, the donor type is not limited.
* 3.ECOG score is 0-2 points.
* 4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.
* 5.One of the following high-risk factors:
* a. Age of initial diagnosis ≥ 35 years old.
* b. Initial diagnosis of WBC ≥ 100 × 109/L.
* c. Initial diagnosis of LDH exceeding the upper limit of normal values.
* d. Initial diagnosis of bone marrow involvement (blast cells ≥ 5%).
* e. Initial diagnosis of a bulky in the mediastinum (longest diameter ≥ 10cm).
* f. ETP immunophenotype.
* g. During the induction chemotherapy process, 2 courses did not achieve partial remission and/or 4 courses did not achieve complete remission.
* h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.
* i. Based on the ELN recommendation based on adult T-ALL: gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations; t (8; 14) (q24; q11)/MYC rearrangement; t (7; 19) (q34; p13)/TCR-LYL1，TCR-MEF2C; del(5q) (q14).
* j. High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.

Exclusion Criteria：

* 1.Central involvement during any course of the disease.
* 2.Patients who have not achieved complete remission before transplantation.
* 3.Identify those with available targeted drugs.
* 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.
* 5.Individuals who are known to be allergic to demethylating drugs or venetoclax.
* 6.Individuals with grade 2 or more degrees of active acute GVHD.
* 7.Individuals with moderate to severe chronic GVHD.
* 8.T-LBL/ALL relapse (flow cytometry abnormal lymphocyte cell proportion\>0.01%, WT1 positive, fusion gene positive, or extramedullary recurrence), or transplant rejection, bone marrow donor cell chimerism\<95%.
* 9.Blood routine: ANC\<1.0 × 109/L or PLT\<50 × 109/L.
* 10.Combined with severe organ dysfunction; The ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) is more than 3 times the normal value or the normal value of direct bilirubin is more than 3 times; The endogenous creatinine clearance rate (Ccr) is less than 50mL/min or 1.5 times the normal value of blood creatinine, regardless of whether hemodialysis treatment is used.
* 11.Merge severe active infections.
* 12.Pregnant or lactating women.
* 13\. Accepting other investigational drugs.
* 14.According to the researchers' assessment, the patient may have complications that could lead to other dangers.

Where it's running

• Shanghai General Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xianmin Song
• Email: shongxm@139.com
• Phone: +8613501672508

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term心理 and cognitive check after stem cell transplant for immune deficiencies

  This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07766304

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• How facial type relates to relapse after orthodontic treatment during retention

  This study tests whether people with different facial types have different patterns of tooth movement relapse after orthodontic treatment during the retention phase.

  Recruiting Postgraduate Institute of Dental Sciences Rohtak · Rohtak, Haryana · NCT07622277

• Can a multi-omics and AI model predict ABPA relapse within 1 year in adults?

  This study tests a machine learning model that uses multi-omics and clinical data to predict the 1-year relapse risk for adults with ABPA who are in a stable state.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07611838

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.